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Five pathologic variants of idiopathic focal segmental
glomerulosclerosis (FSGS) are recognized: collapsing (COLL),
cellular (CELL), glomerular tip lesion (GTL), perihilar, and not
otherwise specified (NOS). The prognostic significance of
CELL FSGS has not been determined. We compared the
presenting clinical and pathologic characteristics in 225
patients with CELL (N¼ 22), COLL (N¼ 56), GTL (N¼ 60), and
NOS (N¼ 87) variants of idiopathic FSGS. CELL, COLL, and tip
lesion all showed greater frequency and severity of nephrotic
syndrome, and shorter time to biopsy compared to NOS.
Predictors of end-stage renal disease (ESRD) for all FSGS
patients included initial serum creatinine, % global sclerosis,
% COLL lesions, chronic tubulo-interstitial injury score, and
lack of remission response. COLL FSGS had the highest rate
of renal insufficiency at presentation, most extensive
glomerular involvement and chronic tubulo-interstitial
disease, fewest remissions (13.2%), and highest rate of ESRD
(65.3%). GTL patients were older and showed the highest
remission rate (75.8%) and lowest rate of ESRD (5.7%). CELL
variant showed intermediate rates of remission (44.5%) and
ESRD (27.8%) compared to COLL and tip lesion. CELL variant
may include cases of unsampled tip or COLL lesion,
underscoring the importance of adequate sampling. Our data
support the view that CELL and COLL FSGS are not equivalent
and validates an approach to pathologic classification that
distinguishes between COLL, CELL, and tip lesion variants
of FSGS.
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A pattern of focal segmental glomerulosclerosis (FSGS)
may result from diverse pathogenetic mechanisms
including heritable mutations of podocyte-specific proteins,
infections, drug toxicities, and adaptive responses to reduced
functioning renal mass.1 For most patients with FSGS
who present with nephrotic syndrome or heavy proteinuria,
no secondary cause is identified (idiopathic FSGS).
Idiopathic FSGS is clinically and pathologically hetero-
geneous and displays variable renal outcomes. Remission of
nephrotic syndrome is the single most important predictor of
long-term renal survival,2–6 but morphologic classification
of FSGS variants may provide additional prognostic
information.2
The Columbia FSGS Classification employs a step-wise,
hierarchical approach to distinguish five mutually exclusive
variants of FSGS: collapsing (COLL), glomerular tip lesion
(GTL), cellular (CELL), perihilar (PH), and not otherwise
specified (NOS) (Figures 1–7).1 The prognostic value of
morphologic classification of idiopathic FSGS is supported
by the observation that COLL FSGS has a more aggressive
clinical course, with fewer remissions and more frequent end-
stage renal disease (ESRD)2,3 whereas GTL identifies a subset
of FSGS that usually responds to steroids and rarely
progresses to ESRD.2,4 In the Columbia FSGS Classification,
CELL is defined by presence of at least one glomerulus with
segmental expansion of the glomerular tuft by endocapillary
hypercellularity, often with foam cells, with or without
hyperplasia of overlying visceral epithelial cells. Importantly,
similar lesions may exist in COLL and GTL. Therefore, the
diagnosis of CELL variant requires prior exclusion of any case
with features of segmental capillary collapse (COLL), or with
confluence of the CELL lesion with the origin of the proximal
tubule (GTL). Using this classification schema, CELL is the
least common variant of FSGS, identified in only 3% of cases
of adult idiopathic FSGS in a recent study; the low number of
CELL cases (n¼ 6) in that study precluded statistical
comparison of outcomes with other FSGS subgroups.2 The
relationship of CELL to COLL FSGS is controversial and
some investigators do not distinguish between these sub-
types.5 Thus, the prognostic significance of CELL FSGS is
undetermined.
In this study, we tested the hypothesis that CELL
represents a distinct clinical–pathologic variant of
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Figure 1 | CELL FSGS showing segmental obliteration of the
glomerular capillary lumina by increased number of endocapil-
lary cells, including endocapillary foam cells. Overlying podocytes
are swollen and contain focal intracytoplasmic protein droplets.
Features of capillary collapse or GTL are not seen. The afferent
arteriole is identified at bottom (Jones silver methenamine stain;
original magnification  400).
Figure 2 | CELL FSGS showing segmental engorgement and
occlusion of glomerular capillary lumina by endocapillary foam
cells, producing an expansile hypercellular lesion. There is a small
adhesion to Bowman’s capsule. No collapse is identified. The vascular
and tubular poles are not identified in this plane of section (Jones
silver methenamine stain; original magnification  400).
Figure 3 | CELL FSGS showing segmental endocapillary
accumulation of foam cells and leukocytes, some of which
are undergoing karyorrhexis. Features of capillary collapse or
GTL are not seen. The afferent arteriole and proximal tubule are
not visualized at this magnification (hematoxylin and eosin stain;
original magnification  600).
Figure 4 | COLL FSGS showing global obliteration of glomerular
capillaries by implosive collapse of glomerular basement
membranes and prominent hypertrophy and hyperplasia of the
overlying podocytes, some of which are detached from the tuft
(Jones silver methenamine stain; original magnification  400).
Figure 5 | Glomerular tip lesion. There is a segmental accumulation
of endocapillary foam cells involving the peripheral glomerular
segment at the tubular pole, adjacent to the origin of the proximal
tubule. Podocytes overlying the segmental lesion show confluence
with proximal tubular epithelial cells. Features of capillary collapse
are not seen. The incoming arteriole is seen at the opposite pole
(PAS reaction; original magnification  250).
Figure 6 | PH FSGS. There is segmental occlusion of glomerular
capillaries by matrix accumulation and hyalinosis at the glomerular
hilus, identified by the incoming afferent arteriole and macula densa.
Features of collapse, GTL, or endocapillary hypercellularity are not
seen (PAS reaction; original magnification  250).
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idiopathic FSGS by comparing the clinical and pathologic
characteristics in a large cohort of patients with either CELL,
COLL, GTL, or NOS in accordance with the Columbia FSGS
Classification.1
RESULTS
Clinical characteristics of CELL and comparison to other FSGS
variants
A total of 225 patients with idiopathic FSGS were studied,
including 22 with CELL, 56 with COLL, 60 with GTL, and 87
with NOS. Demographic characteristics and presenting
clinical features are summarized in Table 1. The cohort of
CELL included 13 males and nine females. The mean age
(7standard error of the mean) of CELL patients was
48.874.9 years and there were two children (ages 9 and 15
years). Seven patients were African-Americans, 12 were
Caucasians, one was non-African American Hispanic, and
two were Asians. Twenty-one CELL patients had nephrotic
range proteinuria (NRP) (mean urinary protein excretion
(UVp) 9.571.2 g/day) and 19 patients (86.4%) fulfilled all
three defining criteria for the nephrotic syndrome
(NRPþ hypoalbuminemiaþ peripheral edema). Two sub-
jects had NRP (3.8 and 4.0 g/day, respectively) but lacked
evidence of edema or hypoalbuminemia and one subject had
2.5 g/day proteinuria, edema, and normal serum albumin
(3.6 g/dl). The mean duration of symptoms before biopsy was
4.370.9 months. In 12 of 14 cases where the onset
of symptoms was described, this was noted as acute,
sudden, recent, or explosive. The mean serum albumin
was 2.170.2 g/dl and mean serum cholesterol was
235.9749.1 mg/dl. Fifteen patients (68.2%) had hyperten-
sion at the time of biopsy that was longstanding in nine cases
and newly diagnosed in six. None of the remaining seven
CELL patients who were normotensive were receiving
antihypertensive medications. At presentation, 12 patients
had renal insufficiency, including one who presented with
ESRD, nine had normal renal function, and renal function
data were not available for one individual. Five CELL subjects
had acute renal insufficiency, based on normal renal function
Figure 7 | FSGS lesion, NOS. There is segmental obliteration
of capillary lumina by accumulation of matrix and hyaline. Features
of collapse, GTL, or endocapillary hypercellularity are not seen.
The tubular and vascular poles are not present in the plane of
section (PAS reaction; original magnification  400).
Table 1 | Baseline clinical characteristics of FSGS patients
Variable All (N=225) CELL (N=22) COLL (N=56) GTL (N=60) NOS (N=87) P=
Age (years) 37.771.3 48.874.9 31.272.3 47.572.3 32.572.0 0.002A
0.004C
o0.001D,F
Male 48.9% 59.1% 46.4% 53.3% 44.8% NS
Black 31.5% 31.8% 53.6% 13.8% 28.9% o0.001D
0.003E
0.044F
Time to Bx (months) 14.272.9 4.370.9 10.072.8 2.170.3 45.2710.9 0.005C
0.045D
0.027E
0.002F
UVp (g/day) 7.270.5 9.571.2 8.871.3 7.870.6 5.170.5 0.033F
Albumin (g/dl) 2.470.1 2.170.2 2.170.2 2.170.1 3.070.1 0.017C
0.001E
o0.001F
Edema N (%) 161/213 (75.6) 20/22 (90.9) 46/54 (85.2) 54/57 (94.7) 41/85 (48.2) o0.001C,E,F
Cholesterol (mg/dl) 263.8713.7 235.9749.1 297.0732.5 223.3726.3 272.1718.7 NS
Nephrotic syndrome (%) 166/220 (75.5) 19/22 (86.4) 47/55 (85.5) 55/58 (94.8) 45/85 (52.9) 0.003C
o0.001E,F
Creatinine (mg/dl) 2.370.2 1.970.3 3.970.6 1.570.1 1.970.2 0.026A
0.002D
0.012E
Creatinine41.2 mg/dl (%) 115/215 (53.5) 12/21 (57.1) 39/51 (76.5) 23/58 (39.7) 41/85 (48.2) o0.001D
0.001E
HTN (%) 130/206 (63.1) 15/22 (68.2) 33/49 (67.4) 36/57 (63.2) 46/78 (59.0) NS
Bx, biopsy; CELL, cellular FSGS; COLL, collapsing FSGS; GTL, glomerular tip lesion variant FSGS; NOS, FSGS, not otherwise specified; HTN, hypertension (including those with
normal blood pressure receiving anti-hypertensive medication); N, number; NA, not available; NS, not significant; UVp, urinary protein excretion.
Quantitative variables are mean7standard error of mean.
A, CELL vs COLL; B, CELL vs GTL; C, CELL vs NOS; D, COLL vs GTL; E, COLL vs NOS; F, GTL vs NOS.
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tests in the recent past; baseline renal status of the other seven
individuals with renal insufficiency was unknown.
CELL and GTL patients were significantly older than
COLL and NOS (all Po0.005). COLL showed a significantly
higher proportion of black patients compared to GTL and
NOS (both Po0.005) but not compared to CELL. NOS also
showed significantly higher percentage of black patients than
GTL. CELL, COLL, and GTL all showed significantly shorter
time to biopsy than NOS (GTLoCELLoCOLLoNOS).
However, the difference between CELL and COLL (4.370.9
vs 10.072.8 months) did not reach statistical significance.
Among 220 cases of idiopathic FSGS with sufficient clinical
data, 75.5% of patients presented with the nephrotic
syndrome. The mean UVp for all patients was 7.270.5 g/
day, mean serum albumin was 2.470.1 g/dl, and mean serum
creatinine was 2.370.2 mg/dl. CELL, COLL, and GTL all
showed a greater frequency of nephrotic syndrome and lower
serum albumin than NOS, but there was no significant
difference between CELL, COLL, and GTL. Cholesterol levels
were similar in all four groups. COLL showed significantly
higher initial serum creatinine than CELL, GTL, and NOS,
and more frequent renal insufficiency (serum creatini-
ne41.2 mg/dl) than GTL or NOS. The frequency of
hypertension was similar in all four histologic subgroups.
Pathologic findings in CELL and comparison to other FSGS
variants
Renal pathologic findings in CELL and the other FSGS
variants are presented in Table 2. By light microscopy, the
total number of glomeruli in CELL biopsies ranged from 7 to
26 (mean 14.671.3). The percentage of globally sclerotic
glomeruli in CELL cases ranged from 0 to 47% (mean
13.673.0%) and the percentage of segmental lesions per
biopsy ranged from 4 to 30% (mean 17.172.9%). Most
CELL biopsies showed mild tubulo-interstitial scarring
(mean score 1.1, scale 0–3). No tubular microcysts were
seen. Features of acute tubular injury were present in six
biopsies, all from patients with renal insufficiency. Arterio-
sclerosis was present in 13 biopsies and this was mild (1þ )
in nine and moderate (2þ ) in four (mean score 0.870.2).
Immunofluorescence microscopy in all 22 CELL biopsies
was either completely negative or showed segmental glomer-
ular staining for IgM and/or C3 consistent with nonspecific
trapping.6 Electron microscopy (EM) was performed in 19
cases. EM showed 95–100% foot process effacement in 18
cases and 60% effacement in one case. No endothelial
tubuloreticular inclusions or structural glomerular basement
membrane abnormalities were identified.
By definition, all CELL biopsies contained at least one
CELL segmental lesion (range 1–4 per biopsy, mean 2)
(Figures 1–3) and none showed features of COLL (Figure 4)
or GTL (Figure 5). CELL lesions were generally small,
involving 25–50% of the glomerular tuft. In 11 cases, CELL
lesions contained foam cells (Figures 1 and 2); in the other
11 cases, CELL lesions contained mononuclear cells or
neutrophils some of which were undergoing pyknosis or
karyorrhexis (Figure 3). None of these lesions showed
fibrinoid necrosis. Five of the 11 cases with foam cells also
contained infiltrating mononuclear cells or neutrophils. All
22 CELL cases displayed mild (n¼ 13) or moderate (n¼ 9)
visceral epithelial cell hypertrophy and hyperplasia overlying
at least one CELL lesion (Figure 1) but not every CELL lesion
had this feature. Twenty cases contained CELL lesions whose
relationship to the glomerular hilus and proximal tubule was
indeterminate. Peripheral CELL lesions were seen in five
cases, three of which also showed CELL lesions of
indeterminate location in other glomeruli and two of which
showed only peripheral lesions. Importantly, none of these
peripheral CELL lesions showed features of GTL (Figure 5) in
adjacent serial sections. No PH lesions (Figure 6) were seen in
Table 2 | Comparison of pathologic features of FSGS cases
All (153) CELL (22) COLL (46) GTL (49) NOS (36) P=
# Glomeruli 26.372.4 14.671.3 33.875.0 25.172.9 26.376.9 0.005A
0.017B
% Global sclerosis 15.671.6 13.673.0 23.873.6 7.872.0 17.073.6 0.001D
% Collapsing 5.771.0 0 26.673.2 0 0 NA
% Cellular 5.170.6 14.071.6 1.570.6 12.371.4a 0 o0.001A,D
% Perihilar 1.870.4 0 2.470.9 0.170.1 4.972.4 0.003C, 0.005F
% NOS 14.971.0 3.171.3 5.671.2 3.970.9 24.973.1 o0.001C,E,F
% Global sclerosis+% segmental lesionsb 43.072.3 31.473.4 61.973.7 26.172.7 46.874.7 o0.001A,D
0.003F
TA/IF score (0–3+) 1.370.1 1.170.1 1.970.1 0.770.1 1.370.2 o0.001A,D,E
0.001F
Arteriosclerosis 0.970.1 0.870.2 1.170.1 0.770.1 1.070.1 NS
% FP fusion 84.272.0 95.672.2 76.474.2 93.671.4 70.975.1 0.001A
0.002C,D,F
CELL, cellular FSGS; COLL, collapsing FSGS; FP, foot process; GTL, glomerular tip lesion variant FSGS; IF, immunofluorescence microscopy; NOS, FSGS, not otherwise specified;
N, number; NA, not applicable; TA/IF, tubular atrophy and interstitial fibrosis.
Variables are mean7standard error of mean.
A, CELL vs COLL; B, CELL vs GTL; C, CELL vs NOS; D, COLL vs GTL; E, COLL vs NOS; F, GTL vs NOS.
aMostly GTL.
bSegmental lesions include all collapsing, cellular, perihilar or NOS lesions.
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any case of primary CELL. Parenthetically, PH sclerosis had
been seen in three of the six cases of secondary CELL
excluded on the initial review. Seventeen CELL cases (77.3%)
showed only CELL lesions whereas five biopsies (22.7%)
showed both CELL and NOS lesions (Figure 7); the
percentage of segmental lesions that were NOS in these five
biopsies was 33, 50, 60, 60, and 75%, respectively.
The total number of glomeruli in CELL cases (14.671.3)
was significantly less than COLL (33.875.0, P¼ 0.005) or
GTL (25.172.9, P¼ 0.017), but not compared to NOS
(26.376.9, P¼NS). The five CELL cases with NOS lesions
had higher % total segmental lesions than the 17 CELL cases
without NOS lesions (25.673.5 vs 15.873.1%, Po0.001).
However, there was no significant difference in the % CELL
lesions between these two groups (12.1173.1% with NOS
lesions vs 15.873.1% without NOS lesions). COLL showed
significantly greater % global sclerosis than GTL (23.873.6
vs 7.872.0%, P¼ 0.001) and significantly more segmental
lesions of any type (38.173.0) than CELL (17.172.9,
Po0.001) or GTL (18.371.8, Po0.001). COLL showed
significantly greater total glomerular involvement (globalþ
segmental lesions) (61.973.7%) than CELL (31.473.4%,
Po0.001) and GTL (26.172.7%, Po0.001). Compared to
NOS, GTL showed significantly fewer segmental lesions
(Po0.047) and fewer total lesions (globalþ segmental)
(P¼ 0.003).
CELL showed significantly greater % cellular lesions
(14.071.6) than COLL (1.570.6%) (Po0.001), but not
compared to GTL (12.371.4%, P¼NS). CELL and GTL
showed similar % global sclerosis (13.673.0 vs 7.872.0%),
% all segmental lesions (17.172.9 vs 18.371.8%), % NOS
lesions (3.171.3 vs 3.970.9%), tubular atrophy/interstitial
fibrosis score, arteriosclerosis score, and % foot process
effacement (all P¼NS). NOS showed significantly more
NOS lesions (24.973.1%) than any other group (all
Po0.001). Most segmental lesions in GTL (including tip
lesions) were cellular (mean 84% of all segmental lesions);
the remaining lesions were sclerosing tip lesions, NOS, or PH
lesions. PH lesions (Figure 6) were encountered in 10/46
COLL cases, 1/49 GTL cases, and 14/36 cases of NOS; in none
of these cases did PH constitute 450% of segmental lesions.
NOS cases had higher mean % PH lesions (4.972.4%) than
CELL (0%, P¼ 0.003) and GTL (0.170.1%, P¼ 0.005).
COLL showed significantly more severe chronic tubulo-
interstitial injury than all other variants (all Pp0.001) and
GTL showed significantly less chronic tubulo-interstitial
injury than NOS (P¼ 0.001). All four subtypes showed
similar arteriosclerosis score. Both CELL and GTL showed
significantly higher % foot process effacement than COLL
and NOS, but not compared to each other (95.672.2 vs
93.671.4%, P¼NS).
Treatment and outcomes for CELL and comparison to other
FSGS variants
Follow-up data were available for 187 of 225 FSGS patients
(83.1%) including 18 CELL, 53 COLL, 33 GTL, and 83 NOS.
Most patients (72.4%) received steroid therapy; however,
details about duration and dose were not available in many
cases. The majority of patients (51.3%) also received
angiotensin-converting enzyme inhibitor (ACE) and/or
angiotensin receptor blocker (ARB). After a median follow-
up of 20.0 months, 38.5% of all FSGS patients had either
complete or partial remission of nephrotic syndrome and
30.7% progressed to ESRD (Table 3).
Three CELL patients were lost to follow-up shortly after
the biopsy and one died of a myocardial infarction before
therapy for renal disease was initiated. The mean length of
follow-up for the remaining 18 CELL patients was 17.473.3
months (median 15.5 months, range 2–49 months). Sixteen
patients received treatment for their renal disease including
14 who received steroids (eight of whom also received ACE
and/or ARB) and two who received ACE/ARB alone. Among
the patients treated with steroids: four also received
sequential therapy with cyclosporine A, including one who
later received cyclophosphamide; and two also received
mycophenolate mofetil, followed by tacrolimus in one
individual. Two CELL patients did not receive therapy,
including one who presented with ESRD and one subject
who was diagnosed with metastatic cancer and cirrhosis
around the time of biopsy; the latter patient had no
remission (NR) at 5 months follow-up.
Following therapy, seven CELL patients entered complete
remission (CR) (including one individual who subsequently
relapsed and had 2.8 g/day proteinuria and stable renal
function at last follow-up). All seven CR patients received
steroids; three also received ACE/ARB; and two received
calcineurin inhibitor, including one who also received
mycophenolate mofetil. Of note, two CR patients had mild
renal insufficiency at presentation (serum creatinine 1.6 and
1.9 mg/dl, respectively) that recovered fully at last follow-up.
Ten CELL subjects were classified as NR, including one
individual who presented with ESRD and one patient who
showed significant reduction in UVp (from 14 to 0.9 g/day)
but who had progressive renal insufficiency at last follow-up
(serum creatinine increased from 1.5 to 2.7 mg/dl). The
remaining eight NR patients all had persistent heavy
proteinuria (urinary protein/creatinine ratio 42). Excluding
the individual who presented with ESRD, the mean initial
serum creatinine in the other nine NR patients was 2.2 mg/dl
(range 0.9–6.3 mg/dl) and the mean final serum creatinine of
those not progressing to ESRD was 2.1 mg/dl (range
0.9–3.7 mg/dl). Five NR subjects received steroids, including
four with ACE/ARB, three with sequential cyclosporine A,
and one each with sequential cyclophosphamide or sequen-
tial mycophenolate mofetil. One NR patient was treated with
ACE/ARB alone. Two NR patients had normal renal function
and heavy proteinuria at last follow-up. In addition to the
one subject who presented with ESRD, four others developed
ESRD (after 8, 10, 28, 35 months, respectively). One of these
four subjects had normal renal function at presentation,
two had renal insufficiency, and initial renal function data for
the other individual was unknown. UVp in NR patients
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decreased from 8.971.9 to 6.272.3 g/day at last-follow-up
(P¼NS). One patient (who was treated with ACE only) had
partial remission (PR) and stable renal function at last
follow-up (UVp 0.4 g/day). At last follow-up, four of the 11
subjects with either NR or PR had stable renal function
(mean follow-up 16.577.5 months, range 1–49 months); two
had worsening renal function (at 23 and 28 months,
respectively); and five were on dialysis.
Of the 12 CELL patients with renal insufficiency at time of
biopsy: one was lost to follow-up; one immediately started
dialysis (ESRD) and six had NR at last follow-up, including
two who progressed to ESRD. The remaining four patients
who had renal insufficiency at the time of biopsy had either
normal or improved renal function at last follow-up.
The mean length of follow-up was significantly longer in
NOS (46.374.7 months) compared to the other three
groups. There was significantly greater use of steroids in
GTL (97.2%) compared to all other groups and significantly
less use of ACE/ARB in COLL (31.0%) compared to CELL
(62.5%, P¼ 0.042) and GTL (66.7%, P¼ 0.006). There was
significantly less use of calcineurin inhibitors in COLL
compared to NOS but no significant difference in use of cyto-
toxic agents among the four FSGS subtypes. Mycophenolate
mofetil was used in only two patients, both with CELL. GTL
showed significantly higher CRþ PR rate (75.8%) compared
to CELL (44.4%, P¼ 0.027), COLL (13.2%; Po0.001), and
NOS (38.6%; Po0.001), and significantly lower ESRD rate
(5.7%) compared to all other groups. COLL showed the
lowest overall remission rate (13.2%) and the highest rate of
ESRD (65.3%). CELL showed intermediate PR and CR rate
(44.4%) compared to COLL (13.2%, P¼ 0.009) and GTL
(75.8%, P¼ 0.027) but not compared to NOS. CELL and
COLL also showed significantly different rates of ESRD
(27.8 vs 65.3%, P¼ 0.023). By Kaplan–Meier analysis, both
Table 3 | Treatment and outcomes of FSGS cases
All CELL COL GTL NOS P=
N with follow-up 187 18 53 33 83
Mean follow-up (months) (median) 33.772.7 (20.0) 17.473.3 (15.5) 25.774.8 (16.0) 21.474.3 (12.0) 46.374.7 (32.0) o0.001C
0.017E
0.001F
Therapy
Steroids 72.4% 77.8% 66.0% 97.2% 63.0% 0.038B
o0.001D,F
ACE/ARB (% yes) 51.3% 55.6% 31.0% 66.7% 49.3% 0.042A
0.006D
CNI 19.5% 27.8% 9.3% 16.7% 30.6% 0.022E
Cytotoxics 17.9% 11.1% 19.2% 13.9% 20.9% NS
MMF 1.3% 11.1% 0.0% 0.0% 0.0% NS
Last sCr (mg/dl) 2.470.2 1.970.6 3.770.8 1.270.1 2.670.3 0.029D
0.002F
Last UPC 2.570.4 3.171.3 3.970.8 2.370.8 2.170.4 NS
Response
CR:PR:NR 51:21:115 7:1:10 4:3:46 20:5:8 20:12:51 0.006A
0.086B
o0.001D,F
0.005E
% CR+PR 38.5 44.4 13.2 75.8 38.6 0.009A
0.027B
o0.001D,F
0.001E
% ESRD 30.7 27.8 65.3 5.7 34.5 0.023A
0.011B
o0.001D,F
0.01E
Kaplan–Meier months survival to ESRD median 72710 3576 23711 (8578)a 90710 0.211A
0.011B
0.0216C
0.0001D
o0.0001E
ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Bx, biopsy; CELL, cellular FSGS; CNI, calcineurin inhibitors; COLL, collapsing FSGS;
CR, complete remission; ESRD, end-stage renal disease; GTL, glomerular tip lesion variant; MMF, mycophenolate mofetil; NOS, FSGS, not otherwise specified; N, number; NA,
not available; NC, not calculable; ND, not done; NR, no remission; NS, not significant; PR, partial remission; sCr, serum creatinine; UPC, urine protein/creatinine ratio.
Categorical variables are % affected; quantitative variables are mean7s.e.m., except where otherwise stated.
A, CELL vs COLL; B, CELL vs GTL; C, CELL vs NOS; D, COLL vs GTL; E, COLL vs NOS; F, GTL vs NOS.
aMean value for GTL provided (median not calculable).
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COLL and CELL showed significantly shorter time
to development of ESRD compared to GTL and NOS;
however, there was no significant difference between CELL
and COLL.
Clinical–pathologic correlations in CELL and all FSGS cases
On average, black CELL patients were younger than non-
black patients (mean age 28.976.7 vs 53.777.2 years,
P¼ 0.025) and were less likely to show remission response
than white patients (P¼ 0.017). Arteriosclerosis score
correlated positively with patient age (linear function,
P¼ 0.008) and with hypertension (P¼ 0.018). Serum crea-
tinine correlated negatively with UVp (logarithmic function,
P¼ 0.035, r¼ 0.566) and UVp correlated negatively with %
segmentalþ global sclerosis (P¼ 0.087, r¼ 0.441), suggesting
that higher protein excretion was not a function of more
advanced glomerular disease. The presence of NOS lesions in
CELL patients correlated with higher serum albumin
(2.8870.39 mg/dl in five patients with NOS vs
1.7170.27 mg/dl in 17 patients without NOS, P¼ 0.024)
suggesting that those without NOS were more nephrotic at
presentation. However, there was no significant correlation
between presence of NOS lesions and edema (P¼ 0.055),
UVp, age, race, gender, serum creatinine, response to therapy,
or rate of ESRD (all P40.10), or time to ESRD by
Kaplan–Meier analysis.
For cases of CELL, the only correlate of any remission
response (complete or partial) was white race (P¼ 0.017).
Inverse correlates of ESRD included any remission response
(CR/PR vs NR, P¼ 0.036) and duration of therapy
(P¼ 0.036) suggesting that these patients had failed to
respond to steroid therapy and that progression to ESRD was
not due to failure to treat. Although five of 10 NR developed
ESRD, compared to zero of eight CR/PR patients, these
differences did not reach statistical significance by Fisher’s
exact test (P¼ 0.06), presumably reflecting the small sample
size and the short follow-up. Similarly, although black
patients were less likely to show remission response, it was
not possible to demonstrate an association between black
race and ESRD, reflecting the small number of events (one of
seven black patients with ESRD versus four of 10 non-black
patients, P¼ 0.624).
By multivariate analysis (Cox regression), no clinical or
pathologic variable correlated with ESRD in CELL cases.
However, when all FSGS patients were combined, predictors
of ESRD included: initial serum creatinine (hazard ratio
(HR) 1.270, confidence interval (CI) 1.192–1.354, Po0.001);
lack of any remission response (CR/PR vs NR) (HR 0.255,
CI 0.131–0.495, Po0.001); % global sclerosis (HR 1.025, CI
1.011–1.039, Po0.001); % COLL lesions (HR 1.016, CI
1.002–1.031, P¼ 0.029); and chronic tubulo-interstitial injury
score (HR 2.345, CI 1.514–3.633, Po0.001). Age, race,
gender, presence or absence of full nephrotic syndrome, UVp,
serum albumin, and arteriosclerosis score were not predictive
of progression to ESRD in the multivariate model for the
whole FSGS population.
DISCUSSION
CELL FSGS, COLL FSGS, and GTL share clinical presenting
features of heavier proteinuria, more frequent nephrotic
syndrome, and shorter duration of symptoms compared
to FSGS NOS, suggesting that these three morphologic
variants reflect acute glomerular injury, or possibly a
response to heavy proteinuria. However, these morphologic
variants of idiopathic FSGS display significantly different
rates of remission and ESRD that are worst for COLL,
intermediate for CELL and NOS, and best for GTL. Among
all FSGS patients, independent predictors of ESRD included
initial serum creatinine, remission response, % glomeruli
with COLL lesions and chronic tubulo-interstitial injury
score, and % global sclerosis. These findings are consistent
with the results of other studies, and support the recognition
of COLL and GTL as distinct clinical–pathologic variants of
FSGS. Although CELL displayed significant differences in
renal outcome compared to COLL and GTL, this might
reflect in part the inclusion of unsampled COLL and GTL in
the CELL cohort, as suggested by the finding that CELL
biopsies had significantly fewer glomeruli than COLL or
GTL.
The initial description of CELL FSGS by Schwartz and
Lewis7 in 1985 did not exclude the presence of COLL features
and these investigators do not distinguish CELL FSGS from
COLL FSGS.5,8 Indeed, two of our initial CELL cases proved
to be COLL based on the finding of segmental capillary
COLL on review of deeper levels. Further evidence that CELL
and COLL may be pathogenetically related includes the
demonstration of glomerular epithelial cell proliferation
associated with evidence of a dysregulated podocyte pheno-
type, including altered expression of cell-cycle regulatory
proteins, in cases of CELL, HIV nephropathy, and idiopathic
COLL.9 These findings raise the important question of
whether CELL should be distinguished from COLL. However,
in the present study we identified significantly different rates
of remission and ESRD when CELL and COLL were classified
as distinct morphologic variants using the Columbia FSGS
Classification. Moreover, % glomeruli with COLL lesions was
an independent predictor of ESRD in all cases of FSGS,
emphasizing the negative prognostic impact of COLL lesions.
These findings support that CELL and COLL lesions should
not be classified together and validates an approach to
pathologic classification that distinguishes between them.
Perhaps the strongest argument for distinguishing CELL
from COLL lesions is that many cases (12 of 38) of apparent
CELL proved to be undersampled GTL after examining
additional (deeper) tissue sections and applying stringent
criteria to define FSGS variants. CELL and GTL showed very
similar pathologic findings including % global sclerosis, %
segmental lesions, % NOS lesions, tubulo-interstitial scar-
ring, arteriosclerosis score, and % foot process effacement,
underscoring the potential for confusion of these subtypes,
particularly in limited biopsy specimens. CELL lesion with-
out tip lesion features might represent a more advanced stage
of GTL where the relationship to the proximal tubule is no
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longer present. In support of this hypothesis is our finding, in
a previous study of GTL, that increased frequency of
peripheral lesions (most of which were cellular) correlated
with higher initial serum creatinine and worse renal
outcomes, including absence of remission and development
of ESRD.4 In the present study, however, GTL and CELL
showed similar mean time to biopsy, initial serum creatinine,
% global glomerulosclerosis, tubular atrophy/interstitial
fibrosis score, and arteriosclerosis score, arguing against
CELL and GTL being different stages of the same disease
process. A minority of CELL cases also contained NOS
lesions; other than the presence of lower serum albumin in
CELL cases with NOS there was no significant difference in
other clinical characteristics, including renal outcomes,
compared to CELL cases without NOS lesions. Given the
possibility that undersampling of either GTL or COLL could
lead to misclassification as CELL, additional tissue sections
are clearly warranted in all biopsies with features of apparent
CELL.
CELL variant of idiopathic FSGS comprised only 3% of all
cases of idiopathic FSGS reported from the University of
North Carolina/Glomerular Disease Collaborative Network
over a 19-year period.2 In the present study, we selected
cohorts of FSGS from different time periods, thus the
frequency of CELL cannot be determined from the data
presented. However, among 6487 consecutive native kidney
biopsies examined between 2000 and 2004 inclusively (the
period when most of our CELL cases were diagnosed), a total
of 716 cases were diagnosed with FSGS of which 446 (62.3%)
were NOS or PH, 170 (23.7%) were COLL, 67 (9.4%) were
GTL, and only 33 (4.6%) were CELL. Thus, CELL is clearly
the least common morphologic variant of FSGS.
The pathogenesis of primary CELL is unknown but a key
role for podocyte injury is evidenced by the findings of
diffuse foot process effacement and glomerular epithelial cell
hypertrophy/hyperplasia in most cases. In the renal allograft,
recurrent FSGS often has CELL or COLL features,10 and this
has been linked to the presence of a circulating permeability
factor in some cases.11 However, the nature of this factor and
its role in CELL in the native kidney has not been
determined. The segmental lesions in CELL show variable
features of endocapillary hypercellularity related to accumu-
lation of inflammatory cells (mostly foamy macrophages,
with or without neutrophils and other mononuclear cells).
Similar findings are seen in GTL and some case of COLL, all
of which are associated with heavy proteinuria, as well as in
other human and experimental diseases characterized by
proteinuria,12 suggesting that the intracapillary hypercellu-
larity might represent a localized inflammatory response to
high transcapillary flux of a protein- and lipid-rich filtrate. Of
note, the lack of correlation of CELL and GTL with serum
cholesterol levels argues against hypercholesterolemia per se
being a major pathogenetic factor in the morphogenesis of
these lesions, although the role of other lipids is unknown.
The higher ESRD rate in COLL may reflect the higher initial
serum creatinine in this subgroup, as demonstrated by Cox
regression analysis. In addition, in the present study COLL
showed the highest degree of pathologic injury, including (%
globalþ segmental lesions) and tubulo-interstitial scarring,
despite shorter mean time to biopsy, suggesting an innately
more aggressive disease rather than delay in recognition.
These differences in ESRD rate also raise the question
whether cellular and tip lesions may represent pre-sclerotic or
even potentially reversible segmental lesions.
The prognostic value of morphologic classification of
FSGS is not universally acknowledged,13 reflecting the
inherent difficulty of accurately classifying focal patterns of
injury based on pathologic examination of limited biopsy
samples, and the potential for different types of lesions to
coexist in individual biopsy samples. Even in larger samples,
the findings of a single glomerulus with diagnostic lesions of
COLL or GTL may have markedly different implications for
renal prognosis, underscoring the inherent problem of
accurately classifying glomerular diseases that produce focal
and segmental pathologic alterations. Nonetheless, given the
findings of major difference in renal outcomes between
COLL and GTL identified in this and other studies, we
believe it is important to recognize CELL as a distinct
morphologic lesion (defined by segmental expansion of the
glomerular tuft with endocapillary hypercellularity, without
features of COLL or GTL). Classification of all CELL cases as
COLL would inevitably lead to inclusion of some cases of
GTL where the defining tip lesion was not sampled, thereby
diluting the prognostic significance of both COLL and GTL.
In summary, CELL identifies patients with idiopathic
FSGS who present with short duration of heavy proteinuria/
nephrotic syndrome, which, if unremitting, may lead to
ESRD. As such, CELL lesions represent a feature of active
FSGS. On deeper sectioning, some cases of CELL variant
prove to be GTL or, less commonly, COLL variants. These
sampling problems may explain in part the intermediate
outcome of CELL relative to COLL and GTL. Despite
these limitations of sampling, our data strongly support the
view that CELL and COLL lesions are not equivalent. The
different clinical features and prognostic implications of
COLL, CELL, and GTL validate an approach to pathologic
classification of FSGS that distinguishes between these
morphologic subtypes.
MATERIALS AND METHODS
Case selection
A database search of all native kidney biopsies that were accessioned
at the Columbia University Medical Center Renal Pathology
Laboratory between 1998 and 2005 (inclusively) identified 48 cases
that were originally diagnosed as CELL. Six cases of probable
secondary FSGS were excluded, including three cases of hypertensive
arterionephrosclerosis, one associated with morbid obesity, one with
renal atheroembolic disease, and one case associated with solitary
kidney. Three cases that showed immunofluorescence microscopy
and EM features of C1q nephropathy, and one case that had less
than five glomeruli by combined light and EM were also excluded.
To rule out undersampled COLL or GTL, additional tissue sections
were obtained on each of the remaining 38 cases. The pathologic
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findings were jointly re-reviewed by three renal pathologists using a
multiheaded optical microscope to arrive at a consensus diagnosis.
Sixteen of these 38 cases were re-classified as GTL (n¼ 12), COLL
(n¼ 2), or NOS (n¼ 2) based on the recently published Columbia
Classification scheme (see below) and examination of deeper tissue
sections. For comparison of demographic and clinical presenting
features with the 22 CELL cases, three cohorts were selected,
including 56 cases of COLL (diagnosed between 1979 and 2001), 60
cases of GTL (diagnosed between 1998 and 2004), and 87 cases of
NOS (diagnosed between 1979 and 2000). Details of some of these
cases have been reported previously.3,4 In the majority of cases, glass
slides were available for re-review, including 46 cases of COLL, 49
cases of GTL, and 36 cases of NOS, and the morphologic
classification of FSGS subtype in accordance with the Columbia
FSGS classification scheme was confirmed. Only cases with 45
glomeruli per tissue section were included. In all cases, known
secondary causes of FSGS were excluded, including HIV infection,
intravenous drug use, vesico-ureteral reflux, chronic glomerulone-
phritis, morbid obesity, and familial renal disease. We did not
include the PH subgroup because many of these cases represent
secondary forms of FSGS owing to adaptive responses and the focus
of this study was the comparison of pathologic variants of idiopathic
FSGS. The Institutional Review Board of Columbia University
Medical Center approved this study.
Clinical characteristics of FSGS patients
Clinical data were obtained from physician referral forms submitted
at the time of biopsy and from follow-up telephone conversations.
For adults (X16 years of age), the following clinical definitions were
used: NRP, X3.5 g/day; hypoalbuminemia, serum albumin o3.5 g/
dl; hypercholesterolemia, serum cholesterol 4200 mg/dl; and renal
insufficiency, serum creatinine 41.2 mg/dl. Nephrotic syndrome
was defined as two or more findings of NRP, hypoalbuminemia, and
peripheral edema. Hypertension was defined as systolic blood
pressure 4140 mmHg or diastolic blood pressure 490 mmHg, or
receiving antihypertensive medications. For subjects agedp16 years
at initial presentation, NRP was defined as 440 mg/m2/h;14
hypoalbuminemia was defined as serum albumin o2.5 g/dl,14 renal
insufficiency was defined by a calculated creatinine clearance of less
than 90 cm3/min,15 and hypertension was defined as a systolic or
diastolic blood pressure 4the 90th percentile based on the child’s
gender, age, and height percentile.16 ACE/ARB were considered
antihypertensive medications only where used specifically for the
treatment of hypertension, not proteinuria. For outcome analysis,
stable renal function was defined as a change in serum creatinine of
p20% of the initial value. CR was defined as UVp o0.3 g/day,
random urine protein/creatinine ratio of p0.3, or dipstick trace
protein, and stable renal function at last follow-up. PR was defined
as UVp of 0.3–2 g/day, or urinary protein/creatinine ratio of 0.3–2,
with at least 50% reduction in proteinuria from initial presentation,
and stable renal function at last follow-up. NR was defined as
persistent heavy proteinuria (42 g/day, or urinary protein/creati-
nine ratio42) and/or progressive renal failure at last follow-up.
ESRD was defined as the time point when renal replacement therapy
was started.
Pathologic classification of FSGS
Renal biopsies were processed for light microscopy, immunofluor-
escence microscopy and EM according to standard techniques. For
light microscopy, at least 11 glass slides, each containing 2–3 tissue
sections (3 mm thick), were stained with hematoxylin and eosin,
periodic acid-Schiff (PAS), Masson’s trichrome and Jones silver
methenamine stains. To minimize undersampling of COLL lesions
or GTL, additional sections were obtained for all CELL cases (one
PAS slide with 3–6 tissue sections per case). Routine immunofluor-
escence microscopy was performed on 3 mm thick cryostat sections
using polyclonal fluorescein isothiocyanate-conjugated antibodies to
IgG, IgM, IgA, C3, C1q, k, l, fibrinogen, and albumin (Dako
Corporation, Carpinteria, CA, USA). EM was performed using a
JEOL 100S electron microscope.
The percentage of globally sclerotic glomeruli and segmental
lesions in each biopsy was calculated. Each lesion was categorized
according to the Columbia FSGS Classification and each case was
subsequently assigned to one of the FSGS variants.1 COLL lesion was
defined by the presence of either segmental or global glomerular
capillary wall COLL with hypertrophy and hyperplasia of overlying
podocytes (Figure 4). Tip lesion was defined by the presence of a
segmental lesion involving the tip domain (the outer 25% of the tuft
next to the origin of the proximal tubule), in which the tubular pole
was identified and there was either an adhesion or confluence of
podocytes with parietal or tubular epithelial cells at the tubular
lumen or neck (Figure 5). CELL lesion was defined as occlusion
of capillary lumina by segmental endocapillary hypercellularity
(Figure 1), with or without foam cells, hyalinosis, and karyorrhexis,
but without features of segmental COLL or tip lesion in this or
any other glomerulus in the biopsy. CELL lesions could show
podocyte hyperplasia and hypertrophy (Figure 1) but this feature
was not required for diagnosis. CELL lesions could be located
adjacent to the hilus (PH) or in the tuft periphery (peripheral). In all
cases where peripheral CELL lesions were identified, adjacent tissue
sections were carefully screened to exclude GTL. PH FSGS lesions
consisted of hyalinosis or sclerosis contiguous with glomerular hilus
(Figure 6), whereas NOS lesions consisted of segmental increase in
matrix obliterating the capillary lumina, without features of COLL,
tip lesion, endocapillary hypercellularity, or PH localization
(Figure 7).
COLL variant FSGS was diagnosed if at least one glomerulus
showed a segmental or global COLL lesion, regardless of findings in
the remaining glomeruli. GTL was diagnosed if tip lesions were
found, without evidence of COLL features in any glomerulus. CELL
variant FSGS contained CELL lesions that lacked features of COLL
or GTL whereas NOS variant was diagnosed by the presence of an
NOS lesion in at least one glomerulus, after exclusion of COLL,
GTL, or CELL. Of note, no case in this study showed features of PH
variant FSGS (450% PH segmental lesions, after excluding cases of
COLL, GTL, CELL).
For CELL cases, the location of each segmental lesion with respect
to the glomerular hilus and tubular pole was determined by tracking
through adjacent tissue sections. The degree of podocyte hyperplasia
and hypertrophy in each segmental lesion was graded semiquantita-
tively (mild, moderate, or severe) and the presence or absence of foam
cells, mononuclear cells, and neutrophils were noted. Acute tubular
injury was defined by the presence of tubular simplification, loss of
brush border, and enlarged reparative nuclei with nucleoli, with or
without mitotic figures. Tubular atrophy, interstitial fibrosis, inter-
stitial edema, interstitial inflammation, and acute tubular injury were
each graded semiquantitatively on a scale of 0–3þ based on the
% cortical area affected (absent, o25%, 26–50%, and 450%,
respectively). Arteriosclerosis and arteriolosclerosis were graded
0–3þ (absent, mild, moderate and severe, respectively) based on
the degree of luminal narrowing and vessel wall thickening. The
intensity of immunofluorescence staining was graded on a scale of
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0–3þ . The percentage of foot process effacement was determined
quantitatively by estimation (without using morphometric measure-
ments) based on examination of the ultrastructure of all non-sclerotic
glomerular capillaries in all fields studied.
Statistical analysis
Statistical analysis was performed using non-parametric exact
statistical methods, including the Fisher exact test (for categorical
variables), the Wilcoxon rank sum (or Mann–Whitney U) test (for
continuous variables between two groups), the Kruskal–Wallis and
the Jonckheere–Terpstra test (for continuous variables among 3þ
groups). Where parametric testing could be applied, comparison
among multiple groups was performed by one-way analysis of
variance. A standard test for homogeneity of variance was used to
guide post hoc analysis (for assumed equal variance: the Tukey and
Bonferroni tests and for unequal variance: the Tamhane and
Dunnett tests). Bivariate comparison of two continuous variables
was performed by standard curve estimation/fitting methods.
ESRD-free survival time was calculated by the method of Kaplan
and Meier and statistical comparison was made using the log-rank
test. The Cox proportional hazard model was used for multivariate
analysis of predictors of progression to ESRD. Analysis was
performed using SPSS 14.0 for Windows (SPSS Inc., Chicago, IL,
USA) and StatXact 6.0 for Windows (Cytel Inc., Cambridge, MA,
USA). Continuous variables are reported as the mean7s.e.m.
Statistical significance was assumed at Po0.05.
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